Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

389 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunovirological status in people with perinatal and adult-acquired HIV-1 infection: a multi-cohort analysis from France.
Seng R, Frange P, Faye A, Dollfus C, le Chenadec J, Boufassa F, Essat A, Goetghebuer T, Arezes E, Avettand-Fènoël V, Bigna JJ, Blanche S, Goujard C, Meyer L, Warszawski J, Viard JP; ANRS EPF; COVERTE; PRIMO; SEROPRI; COPANA study groups. Seng R, et al. Among authors: viard jp. Lancet Reg Health Eur. 2024 Apr 1;40:100885. doi: 10.1016/j.lanepe.2024.100885. eCollection 2024 May. Lancet Reg Health Eur. 2024. PMID: 38576825 Free PMC article.
Changes in cancer mortality among HIV-infected patients: the Mortalité 2005 Survey.
Bonnet F, Burty C, Lewden C, Costagliola D, May T, Bouteloup V, Rosenthal E, Jougla E, Cacoub P, Salmon D, Chêne G, Morlat P; Agence Nationale de Recherches sur le Sida et les Hépatites Virales EN19 Mortalité Study Group; Mortavic Study Group. Bonnet F, et al. Clin Infect Dis. 2009 Mar 1;48(5):633-9. doi: 10.1086/596766. Clin Infect Dis. 2009. PMID: 19202627
High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.
Yazdanpanah Y, Fagard C, Descamps D, Taburet AM, Colin C, Roquebert B, Katlama C, Pialoux G, Jacomet C, Piketty C, Bollens D, Molina JM, Chêne G; ANRS 139 TRIO Trial Group. Yazdanpanah Y, et al. Clin Infect Dis. 2009 Nov 1;49(9):1441-9. doi: 10.1086/630210. Clin Infect Dis. 2009. PMID: 19814627 Clinical Trial.
Association of prenatal and postnatal exposure to lopinavir-ritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers.
Simon A, Warszawski J, Kariyawasam D, Le Chenadec J, Benhammou V, Czernichow P, Foissac F, Laborde K, Tréluyer JM, Firtion G, Layouni I, Munzer M, Bavoux F, Polak M, Blanche S; ANRS French Perinatal Cohort Study Group. Simon A, et al. JAMA. 2011 Jul 6;306(1):70-8. doi: 10.1001/jama.2011.915. JAMA. 2011. PMID: 21730243
A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure.
Marcelin AG, Delaugerre C, Beaudoux C, Descamps D, Morand-Joubert L, Amiel C, Schneider V, Ferre V, Izopet J, Si-Mohamed A, Maillard A, Henquell C, Desbois D, Lazrek M, Signori-Schmuck A, Rogez S, Yerly S, Trabaud MA, Plantier JC, Fourati S, Houssaini A, Masquelier B, Calvez V, Flandre P; ANRS AC11 Resistance Group. Marcelin AG, et al. Int J Antimicrob Agents. 2013 Jul;42(1):42-7. doi: 10.1016/j.ijantimicag.2013.02.016. Epub 2013 Apr 4. Int J Antimicrob Agents. 2013. PMID: 23562640
Transmitted drug resistance in French HIV-2-infected patients.
Charpentier C, Visseaux B, Bénard A, Peytavin G, Damond F, Roy C, Taieb A, Chêne G, Matheron S, Brun-Vézinet F, Descamps D; ANRS CO5 HIV-2 Cohort. Charpentier C, et al. AIDS. 2013 Jun 19;27(10):1671-4. doi: 10.1097/QAD.0b013e32836207f3. AIDS. 2013. PMID: 23595155
389 results